122 related articles for article (PubMed ID: 38546066)
21. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
22. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma.
Dimopoulos MA; Beksac M; Benboubker L; Roddie H; Allietta N; Broer E; Couturier C; Mazier MA; Angermund R; Facon T
Haematologica; 2013 Aug; 98(8):1264-72. PubMed ID: 23716559
[TBL] [Abstract][Full Text] [Related]
24. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
[TBL] [Abstract][Full Text] [Related]
25. Cell division cycle 37 change after bortezomib-based induction therapy helps to predict clinical response and prognosis in multiple myeloma patients.
Lin W; Chen X; Zheng H; Cai Z
Hematology; 2023 Dec; 28(1):2231741. PubMed ID: 37409850
[TBL] [Abstract][Full Text] [Related]
26. Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma.
Xu Y; Deng S; Mao X; An G; Li Z; Wang Y; Fulciniti M; Ho M; Lin J; Sui W; Liu W; Zou D; Yi S; Huang W; Liu H; Lv R; Li J; Wang T; Du C; Munshi NC; Qiu L
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):422-430. PubMed ID: 29625927
[TBL] [Abstract][Full Text] [Related]
27. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma.
Bagratuni T; Terpos E; Eleutherakis-Papaiakovou E; Kalapanida D; Gavriatopoulou M; Migkou M; Liacos CI; Tasidou A; Matsouka C; Mparmparousi D; Dimopoulos MA; Kastritis E
Br J Haematol; 2016 Jan; 172(1):44-7. PubMed ID: 26564000
[TBL] [Abstract][Full Text] [Related]
28. Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Buda G; Ricci D; Huang CC; Favis R; Cohen N; Zhuang SH; Harousseau JL; Sonneveld P; Bladé J; Orlowski RZ
Ann Hematol; 2010 Nov; 89(11):1133-40. PubMed ID: 20532504
[TBL] [Abstract][Full Text] [Related]
29. Daratumumab and antineoplastic therapy versus antineoplastic therapy only for adults with newly diagnosed multiple myeloma ineligible for transplant.
Langer P; John L; Monsef I; Scheid C; Piechotta V; Skoetz N
Cochrane Database Syst Rev; 2024 May; 5(5):CD013595. PubMed ID: 38695605
[TBL] [Abstract][Full Text] [Related]
30. Hematological, Biochemical and Renal Changes in Patients of Multiple Myeloma Treated with Bortezomib Based Triple Drug Chemotherapy.
Panda T; Das S; Jena RK; Das BP; Rout SB
J Assoc Physicians India; 2019 Jul; 67(7):54-57. PubMed ID: 31559769
[TBL] [Abstract][Full Text] [Related]
31. Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.
Fristedt Duvefelt C; Lub S; Agarwal P; Arngården L; Hammarberg A; Maes K; Van Valckenborgh E; Vanderkerken K; Jernberg Wiklund H
Oncotarget; 2015 Aug; 6(24):20621-35. PubMed ID: 26036313
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival.
Andersen NF; Vogel U; Klausen TW; Gimsing P; Gregersen H; Abildgaard N; Vangsted AJ
Eur J Haematol; 2015 Jan; 94(1):60-6. PubMed ID: 24954766
[TBL] [Abstract][Full Text] [Related]
33. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
34. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
35. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib-based regimens improve the prognosis of newly diagnosed MM patients with chromosomal aberrations except for del(17q13): A retrospective study from a single center.
Liu Z; Zeng Q; Xiang B
Medicine (Baltimore); 2021 May; 100(18):e25834. PubMed ID: 33950994
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice.
Terpos E; Katodritou E; de la Rubia J; Hungria V; Hulin C; Roussou M; Delforge M; Bries G; Stoppa AM; Aagesen J; Sargin D; Belch A; Ahlberg L; Diels J; Olie RA; Robinson D; Spencer M; Potamianou A; van de Velde H; Dimopoulos MA
Eur J Haematol; 2018 Oct; 101(4):556-565. PubMed ID: 30027641
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of serum glucose-regulated protein 78 (GRP78) as a biomarker of treatment response to bortezomib-based induction regimen in multiple myeloma: A cross-sectional pilot study.
Ramachandran SS; Gupta P; Kumar L; Gupta R; Goel L; Kumar VL; Gupta YK
Neoplasma; 2022 Dec; 69(6):1451-1458. PubMed ID: 36591800
[TBL] [Abstract][Full Text] [Related]
39. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E; Katodritou E; Tsiftsakis E; Kastritis E; Christoulas D; Pouli A; Michalis E; Verrou E; Anargyrou K; Tsionos K; Dimopoulos MA; Zervas K;
Haematologica; 2009 Mar; 94(3):372-9. PubMed ID: 19252175
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).
Tessenow H; Holzvogt M; Holzvogt B; Andrea M; Heyn S; Schliwa T; Schwarz M; Zehrfeld T; Becker C; Pfrepper C; Franke GN; Krahl R; Jentzsch M; Leiblein S; Schwind S; Bill M; Vucinic V; Lange T; Niederwieser D; Pönisch W
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2049-2058. PubMed ID: 28534173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
